Securities code: Anhui Anke Biotechnology (Group)Co.Ltd(300009) securities abbreviation: Anhui Anke Biotechnology (Group)Co.Ltd(300009)
Anhui Anhui Anke Biotechnology (Group)Co.Ltd(300009) Engineering (Group) Co., Ltd
Record of investor relations activities
No.: 2022001
Investor relations activities □ specific object research □ analyst meeting
Category □ media interview □ performance briefing
□ press conference □ Roadshow
□ site visit
√ others (teleconference)
Names of participating units and Sinolink Securities Co.Ltd(600109) , Guosheng securities, Guolian Securities Co.Ltd(601456) , lava assets, noan fund, names of Thai personnel, Manulife, Boshi fund, Qianhai Kaiyuan fund, Shanghai Investment Morgan fund, sunshine assets, Tianhong fund, Huaan Securities Co.Ltd(600909) , Soochow Securities Co.Ltd(601555) , Danshui spring, Minghe investment, Yide capital, meiruihongding wealth, naxuan assets, Jiutai fund, Haoshan assets Anxin, Guohua life, Jiuyang Runquan, yuanxiong life, Ruiyang, Hanlun, juqiyuan assets, Xiangju capital, Hongmao assets, GF fund, Orient Securities Company Limited(600958) asset management, Lizheng, lingzhan private placement, CCB pension, Haifutong fund, Xingtu asset management, Caixin trust, Bodao fund, Guangdong cheese, Shanghai Anbo, Junmao and Xishan capital
Time: 10:00-11:00, March 31, 2022; 14:00—15:00
Location teleconference
Name of the receptionist of the listed company: Mr. Li Kun, Secretary of the board of directors of the company
Mr. Li Kun, Secretary of the board of directors of the company, first introduced in detail the company’s operation, investor relations activities and R & D Progress in 2021:
The company adheres to the business philosophy of stable, healthy and rapid development, and the work of R & D, production, sales and other projects are closely promoted around the objectives and directions set in early 2021.
A. Operating conditions: the company achieved a total operating revenue of 2.169 billion yuan, an increase of 27.47% over the same period last year. Since its listing, the compound growth rate of operating revenue has exceeded 20%; The total profit was 295 million yuan, a decrease of 29.08% over the same period last year; The net profit attributable to the owners of the parent company was 207 million yuan, a decrease of 42.44% over the same period last year. After impairment reduction in 2021, the company’s net profit was 551 million yuan, an increase of 53.58% over the same period last year. Since the company was listed in 2009, excluding the impact of goodwill impairment and long-term investment impairment, the compound growth rate of net profit from 2009 to 2021 was 23.32%, and the deduction of non net profit after impairment reduction was 502 million yuan, an increase of 58.95% over the same period last year.; Among them, the parent company performed well. The operating revenue of the parent company increased by 43.08% year-on-year, exceeding 1 billion yuan for the first time, and the sales revenue of growth hormone products exceeded 1 billion yuan for the first time.
B. R & D progress and construction of important product production lines:
In 2021, the company invested 211 million yuan in R & D. As the first antibody product to be applied for production in the field of anti-tumor drugs, the application for marketing license of recombinant human HER2 monoclonal antibody for injection (Product Name: trastuzumab for injection) has been accepted by the State Drug Administration. This product is the second trastuzumab biological similar drug product to be applied for marketing in China. In 2021, it successfully passed the on-site verification of trastuzumab for injection drug registration / production and GMP compliance inspection. At present, the review and approval work related to the application for production is in progress, and this product is expected to become a new growth point of the company in the future. The recombinant anti VEGF humanized monoclonal antibody injection developed by the company has completed the enrollment of phase III clinical trial cases. At present, the product has entered the production preparation stage. The product will be the second item of the company’s application for the production of antibody products in the field of antitumor drugs; The company’s recombinant anti-pd1 humanized monoclonal antibody injection has also completed phase I clinical trial. After the above products are approved for production, it will further enrich the company’s anti-tumor product line, improve the strategic layout of the company’s precision medicine and have a positive impact on improving the core competitiveness.
In 2021, the company approved two new indications for human growth hormone based on the existing indications: (1) idiopathic short stature (ISS); (2) Growth disorder of girls caused by gonadal hypoplasia (Turner syndrome). Among them, the company’s growth hormone is the first approved ISS indication product in China. So far, the company has been approved to list 8 indications of human growth hormone, and the company is the enterprise with the most approved indications of growth hormone in China. In addition, the new production line with an annual output of 20 million human growth hormone for injection in the North District of the company has also been officially approved by the State Drug Administration. In addition, in order to further improve patient compliance and meet clinical and market needs, the company’s human growth hormone injection has been approved by the State Drug Administration to add two new specifications: 6iu / 2mg / 0.6ml/bottle and 8iu / 2.66mg/0.8ml/bottle.
“Human interferon” α 2B spray “is the approved product interferon. α For the upgrading and optimization of 2B series preparations, its clinical trial application has also been approved by the State Drug Administration. By the disclosure of the 2021 annual report, phase I clinical study has been completed and phase II clinical study is ready to be carried out.
C. Important R & D and capacity construction plan in 2022: in 2022, the company will actively promote the transformation of products such as “recombinant human follicle stimulating hormone injection, fusion protein long-acting growth hormone product and a bispecific antibody injection” before clinical trial to the clinical trial stage, and actively promote the industrialization of the new production line of recombinant human HER2 monoclonal antibody drugs for injection and the building of precision medical innovation center in the raised investment project as soon as possible. Promote the equipment installation, workshop purification and equipment commissioning of human growth hormone injection (pre filled) production line. Plan and design the new production line of human interferon series products, recombinant anti VEGF humanized monoclonal antibody injection, human growth hormone injection (cartridge bottle) and other products.
According to the future market development of main products and the market prospect of products under research, the company will timely plan and build new production lines to ensure market demand.
Next, the meeting entered the question session. The company communicated with investors on relevant issues, and the records are as follows:
Q1: how about the new cases of growth hormone in 2021? A: the company’s enrollment of new growth hormone patients in 2021 was higher than that in the same period in 2020
Rapid growth. It is estimated that the growth rate of new patients is higher than the industry average.
Q2: what is the impact of Guangdong alliance’s centralized purchase on the company’s sales of growth hormone?
A: on the basis of price for quantity, the company has fully considered the interests of patients, the company and investors, and reduced the product price. In the future, the company will actively improve the brand influence of products and improve the service level to patients, so as to improve the penetration rate of products and sales volume, so as to maximize the interests of shareholders, Reduce the sales impact of price decline.
Q3: what is the risk of future goodwill impairment?
A: the company did not indicate the risk of goodwill impairment in 2022 in the 2021 annual report. The reason is that at present, the company expects that the risk of goodwill impairment in 2022 is low, which is not enough to give risk tips to investors. For specific investment risks, investors are required to pay attention to the risk tips in the periodic report. Q4: what are the advantages of the company in promoting human growth hormone?
A: the company’s human growth hormone injection does not contain preservatives. It is a one-time injection, convenient and easy to operate, and has leading indications. It is the first product with ISS indications approved in China. Human growth hormone has been approved for listing with 8 indications, and the company is currently the enterprise with the most approved indications of growth hormone in China. In 2021, the company has launched the hidden needle device for growth hormone injection, which can realize the whole process of hidden needle injection, help patients alleviate the fear of injection, and the operation is easier, more convenient and safer.
Annex list (if any) none
Date: April 2, 2022
